Enhancing Oral Formulations of Large and Polar APIs
- Company Details
- Products & Services
- White Papers
- Press Releases
- Regional Offices
- Contact Company
Emisphere Restructures Debt Agreements, Providing Greater Stability for Business Growth and Expansion
Emisphere Technologies has announced that it has reached an agreement with MHR Fund Management to waive certain terms of the company's existing obligations under the loan...
Emisphere Highlights Eligen Licensee Novo Nordisk's Entry into Phase 3A Development of Oral Semaglutide
Emisphere Technologies has highlighted that Eligen licensee Novo Nordisk will initiate a global phase 3A development programme with oral semaglutide, a once daily oral formulation of...
Emisphere Signs License Agreement with Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications
Emisphere Technologies has announced it has entered a development and license agreement with Novo Nordisk to develop and commercialise oral formulations of four classes of Novo...
Emisphere Launches Eligen B12, the First Oral Prescription Tablet Proven to Normalize B12 Levels Without an Injection
Emisphere Technologies has announced US commercial availability of Eligen B12, the first and only once-daily oral prescription medical food tablet shown to normalise B12 levels without the need...
Emisphere Announces Positive Phase II OG217SC Data from Eligen Licensee Novo Nordisk
Emisphere Technologies has announced positive Phase II data from Eligen licensee Novo Nordisk concerning...